
198. early experiences azathioprine ulcerative colitis.  note 
caution 
azathioprine administered 10 patients ulcerative colitis classified 
'very severe' 2,'moderately severe' 7 'relatively mild' 1 
patient, conjunction 'standard' therapy adrenal corticosteroids 
8 10 patients.  possible beneficial therapeutic effects 
azathioprine small series evaluated definitively 
concurrent medication preliminary uncontrolled observations. 
however, clinical improvement apparent 8 10 patients; 2 
patients, favorable course occurred absence steroid therapy.  
2 additional patients, favorable course maintained 
administration azathioprine following discontinuance prolonged 
steroid therapy.  1 patient, administration azathioprine 
associated amelioration arthritis pyoderma gangrenosum 
respond use steroids medication.  immuno-suppressive 
observations limited.  established delayed hypersensitivity response, 
reflected various skin tests, unchanged administration 
azathioprine.  azathioprine discernible toxic effects upon kidneys 
liver 2 patients, 1 postnecrotic cirrhosis 
serum hepatitis.  gastro-intestinal symptoms (anorexia, epigastric discomfort, 
nausea) occurred 8 patients.  mild moderate leukopenia developed 8 
patients and, 2 individuals, accompanied thrombocytopenia.  temporary 
alopecia occurred 1 woman.  hematopoietic effects developed within 2 
3 wk therapy azathioprine dosage level 4-6 mg/kg/day. 
azathioprine exert rapid beneficial effect ulcerative colitis 
noted corticotropin adrenal corticosteroids.  therefore, use 
severe ulcerative colitis requiring intensive therapy probably undesirable. 
azathioprine, basis initial observations, may considered 
moderately severe ulcerative colitis, circumstances permitting controlled 
prolonged therapeutic trial adjunct medication, careful 
supervision prevention toxicity, especially leukopenia. 
